PORTAL VEIN THROMBOSIS

This study tests whether the blood thinner apixaban can safely dissolve blood clots in the portal vein that form more than a year after spleen surgery in people with cirrhosis. The study will enroll 20 participants and measure how many achieve complete or partial clot resolution.…

This study looks at whether the blood thinner apixaban can safely dissolve blood clots in the portal vein (the main vein to the liver) that appear more than a year after laparoscopic spleen removal. It involves 20 adults with cirrhosis who had their spleen removed. The goal is to…

This study tests whether adding the blood thinner apixaban to the standard drug carvedilol can prevent serious complications like bleeding, fluid buildup, and liver failure in people with cirrhosis and high blood pressure in the liver. About 220 adults with stable cirrhosis will …

This study follows 700 liver transplant patients to see how portal vein thrombosis (a blood clot in the main vein to the liver) affects recovery and survival. Researchers will compare those with and without clots to find risk factors and build a tool to predict clots before surge…

This study follows 2000 people with severe high blood pressure in the liver (portal hypertension) who receive a procedure called TIPS, which creates a bypass to reduce pressure. Researchers will track survival, need for liver transplant, and complications like confusion or liver …

This study follows 1500 people with cirrhosis and varices who also have a blood clot in the portal vein (the main vein to the liver). Researchers will track who gets better and what factors help the clot dissolve over 1 to 5 years. The goal is to better understand the disease and…